Clinical trials: Healthy Male/Female Subjects
Healthy Volunteer
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
This randomized, single-center, open-label, one-sequence, two-period crossover study in three parts will assess the effects of multiple doses of ketoconazole, rifampicin and ritonavir-boosted atazanavir on the pharmacokinetics of…
- Trial name
- NCT01591850
- Testing
- RO5093151, atazanavir, ketoconazole
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
AZD9056 Relative Bioavailability Study
The aims of this study are to compare the blood levels achieved with a new formulation of AZD9056 to an existing formulation of AZD9056 used in previous studies.
- Trial name
- NCT00908934
- Testing
- AZD9056 formulation Phase III 50 mg (T), AZD9056 formulation Phase IIb 50 mg (R), AZD9056 formulation Phase III 200 mg (T)
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female…
- Trial name
- NCT03430661
- Testing
- ACT-246475, Clopidogrel, Prasugrel
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Viatris Innovation GmbH
Solid Tumours
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in subjects with renal impairment and healthy subjects
- Trial name
- NCT02063204
- Testing
- selumetinib
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Bioavailability of Omega-3 Food Supplements in Healthy Subjects
The study will evaluate the bioavailability of omega-3 based dietary supplements under fasted conditions in healthy adult subjects. Each subject will participate in 5 treatment periods.
- Trial name
- NCT02376621
- Testing
- PronovaPure 150:500 triglycerides, Pronovum PRF-048, Pronovum PRF-037
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pronova BioPharma
Healthy Male and Female Subjects
To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects
Y-4 is a new fixed-dose combination drug product containing two active ingredients of pregabalin and riluzole. The objective is to assess the effect of food on the pharmacokinetics (PK) of pregabalin and riluzole in healthy adult…
- Trial name
- Y-4-LC-03 (NCT07013773)
- Testing
- Y-4 tablet
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Transepidermal Water Loss, Erythema
Skin Protectant Properties of Omeza Collagen Matrix on Damaged Skin
Single-blind within subject comparison study conducted to investigate the skin protectant properties of Omeza Collagen Matrix on damaged skin
- Trial name
- NCT04512274
- Testing
- Test Article
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Omeza, LLC
End-Stage Renal Disease
Feasibility Study of Arterial Stiffness in Hemodialysis Patients
People with kidney failure have a higher chance of getting disease in the blood vessels and this result in a decreased elasticity of the arteries of their body which make them very stiff or hard.
- Trial name
- NCT02196610
- Testing
- Applanation tonometry
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis
Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction
The purpose of this study is to provide profound insight into the supraspinal neuronal mechanisms and networks responsible for lower urinary tract (LUT) control and to verify, amend or adjust neuronal circuitry models established…
- Conditions
- Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, Overactive Bladder, Spinal Cord Injury
- Trial name
- NCT01768910
- Testing
- fMRI, bladder filling, bladder cooling
- Where
- 2 sites in Switzerland
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Effect of Venglustat in Patients With Renal Impairment
Primary Objective: To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics (PK) of Venglustat following a single dose.
- Trial name
- NCT03687554
- Testing
- Venglustat GZ/SAR402671
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Alzheimer's Disease
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
This is a randomized double-blind (investigator and subject blinded), placebo controlled ascending single dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy male and female…
- Trial name
- NCT02648672
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Healthy Male and Female Subjects, Healthy Elderly
Impact Of Everyday Light Exposure Patterns On Health
The aim of the present study is to characterize everyday light conditions of younger and older adults and to consider them in relation to cardiovascular, metabolic and psychological health.
- Trial name
- AgeLight (NCT06908395)
- Testing
- 10-day ambulatory assessment in everyday life combined with two laboratory office days
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- RWTH Aachen University
Healthy
A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects
The study was an assessor-blind, balanced, parallel, randomized, two-treatment, comparative immunogenicity study of multiple doses of subcutaneous (SC) Pegfilgrastim injection (6 mg/0.6 mL; Qilu Pharmaceutical Co., Ltd.
- Trial name
- NCT04651036
- Testing
- QL0605, US Neulasta
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Bioequivalence Study for Acarbose/Metformin FDC
The purpose of this study is to establish the bioequivalence (i.e. similar pharmacokinetics and pharmacodynamics characteristics) between acarbose/metformin FDC (50 mg/500 mg) and loose combination of acarbose (50 mg) and…
- Trial name
- NCT04065581
- Testing
- Acarbose/Metformin FDC(BAY81-9783), Glucobay, Glucophage
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Body Weight Changes
Efficacy Of Trimrox On Body Recomposition And Weight Management (TRCAP21)
Protocol Number: VNI/121/TrimRox: A unique stimulant- and sugar-free TRCAP21 Prodosomed® nutraceutical formulation, TrimROXTM, has been developed in a cGMP and NSF-certified manufacturing facility that is CFR-111 A compliant as…
- Trial name
- VNI (NCT05283525)
- Testing
- Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches, Oxygen Saturation, Total Blood Chemistry
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Victory Nutrition International, Inc.
Healthy
Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy Subjects
Study to compare the bioavailability of Lacidipine and Telmisartan administered as fixed dose combination tablets with the separate Telmisartan and Lacidipine tablets.
- Trial name
- NCT02209649
- Testing
- Lacidipine and Telmisartan fixed dose combination (FDC) tablet, Lacidipine, Telmisartan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Relapsing Remitting Multiple Sclerosis
Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects
A single-dose, randomized, open-label, two-way crossover, two-period, two-sequence, two-treatment, single-center, bioequivalence study of Bafiertam and Vumerity.
- Trial name
- NCT05181215
- Testing
- Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Renal Impairment, Healthy
Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function
The purpose of this study is to evaluate the effect of mild, moderate, or severe renal impairment, or end-stage renal disease (ESRD) requiring hemodialysis (HD), on the safety and tolerability of 1 or 2 single doses of…
- Trial name
- NCT02647918
- Testing
- Sotagliflozin
- Where
- 4 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Healthy
A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood
The main objective of this trial is to investigate the relative bioavailability of batch 1 of the intended commercial tablet formulation (iCF1) of BI 425809 vs batch 2 of the intended commercial tablet formulation (iCF2) of BI…
- Trial name
- NCT03817476
- Testing
- iCF1(T1) 25 milligram BI 425809, iCF2(T2) 25 milligram BI 425809, TF2(R) 25 milligram BI 425809
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Renal Impairment, Healthy Volunteers
A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys
It is hoped that mobocertinib will eventually help people with cancer with severely reduced kidney function. The main aim of this study is to learn about the levels of mobocertinib in the blood and urine of participants with…
- Trial name
- NCT04056455
- Testing
- Mobocertinib
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.